Pausing arthritis drug may boost pneumonia Shot's power
NCT ID NCT07242092
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether temporarily stopping methotrexate for 2 weeks after receiving a pneumonia vaccine (PCV20) helps the vaccine work better in adults with autoimmune rheumatic diseases like rheumatoid arthritis or lupus. About 192 participants with stable, low disease activity will be randomly assigned to either pause methotrexate or continue it as usual. The main goal is to see if more people develop protective antibodies after vaccination.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
20-valent pneumococcal conjugate vaccine (PCV20)
What this could lead to
If it works, this could show that a short break from methotrexate helps the pneumonia vaccine work better in people with rheumatic diseases, potentially improving protection against serious infections.
What could go wrong
This is a small, early-phase trial (192 people) looking at immune markers, not actual infection rates. Pausing methotrexate may cause disease flares in some participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE RHEUMATIC DISEASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••